What to expect at ASH 2017?
News Published on December 8, 2017
The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH 2017) will be hosted in Atlanta from the 9th to the 12th of December 2017, for another exciting round of stimulating discussions and presentations of results in the malignant and non-malignant Hematology field.
Top 10 Therapeutic Areas
Unsurprisingly, Leukemia will be the hottest topic at this year’s ASH meeting, followed by Lymphoma, Anemia and Multiple Myeloma. Other presentations will cover research about Hemorrhage, Myelodysplastic Syndromes and other Blood Coagulation Disorders, in which the interest has remained stable over the past 3 years.
Top 15 Commercial Sponsors Trials over the Last 3 Years
From a trial perspective, you can expect considerable differences in trial discussion activity compared to the past 2 years. With an increase of almost 70% in presentations about trials (427 trials in 2017, compared to 255 trials in 2015), the 59th ASH meeting has 323 new trials in store for its attendees. This trend confirms the commitment of several sponsors to stay ahead and relevant in the field of Hematology.
Most impressive is the increase in trials sponsored by Roche and Johnson & Johnson. Out of the 30 trials Johnson & Johnson is sponsoring this year, half of them are researching Daratumumab in combination with other drugs in Multiple Myeloma, as well as other indications. Roche, on the other hand, is studying combination therapies with Obinutuzumab, mainly in Leukemia and Lymphoma.
Drugs of Interest
Burton’s Tyrosine Kinase Inhibitors (BTK Inhibitors) and CD19 CARTs are still among the preferred modes of action to target in drug development.
With 3 new molecules and 4 trials in Leukemia and Lymphoma, DTRM Biopharma is one of the smaller sponsors that is betting on BTK inhibitors.
Over the past few years, CD19 is also growing in importance as a target in Leukemia with CART-T therapies. With new drugs in development by ADC-Therapeutics, Kite Pharmaceuticals, and Celgene, we expect a competitive battle for market share in Leukemia.